Our Pricing

How Long Do You Take Wegovy for Weight Loss Results?

Published on: June 03, 2026

Understanding how long to take Wegovy for weight loss is essential before starting treatment. Most patients remain on Wegovy for 12-24 months to achieve and maintain clinical weight loss, with initial results typically visible within 8-12 weeks and peak effects at 68 weeks according to STEP trial data [1]. At Cured Pharmacy, our UK prescribers assess your individual treatment duration based on your response, tolerance, and weight management goals.

Wegovy Treatment Duration: What Clinical Trials Show

The landmark STEP clinical trial programme followed patients for 68 weeks (approximately 16 months), during which participants achieved an average 14.9% body weight reduction on the 2.4mg maintenance dose [1]. However, treatment duration varies significantly between individuals based on starting weight, metabolic response, and weight loss targets.

Most UK prescribers recommend a minimum treatment period of 12 months to assess full therapeutic benefit. In clinical practice, many patients continue Wegovy beyond the initial trial period as a long-term weight management strategy, particularly those with obesity-related comorbidities such as type 2 diabetes or hypertension [2]. The MHRA-approved product information does not specify a maximum treatment duration, allowing prescribers to make individualised decisions based on ongoing clinical benefit and tolerability.

Wegovy Timeline: When Do Results Appear?

Weight loss with Wegovy follows a predictable timeline during the dose escalation phase. Most patients notice initial appetite suppression within the first week of starting the 0.25mg dose, though measurable weight reduction typically begins around week 4-8 [1].

The treatment follows a structured 16-week dose escalation schedule: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1.0mg for 4 weeks, 1.7mg for 4 weeks, before reaching the 2.4mg maintenance dose. Peak weight loss generally occurs between weeks 60-68, with the majority of reduction happening in the first 40 weeks of continuous treatment [3].

Month-by-Month Wegovy Results

During months 1-3, patients on the dose escalation schedule typically lose 3-5% of their starting body weight. Months 4-8 represent the most rapid weight loss phase, with an additional 6-10% reduction as the maintenance dose takes full effect. From month 9 onwards, weight loss continues at a slower rate, with most patients reaching their maximum reduction by month 15-16 before entering a weight maintenance phase [1][3].

How Long Should You Stay on Wegovy After Reaching Your Goal Weight?

Clinical evidence suggests that continuing Wegovy after achieving your target weight is crucial for long-term maintenance. The STEP 4 withdrawal trial demonstrated that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within the following year, whilst those who continued treatment maintained their weight loss [4].

UK prescribers typically recommend ongoing Wegovy therapy as a chronic weight management strategy rather than a short-term intervention. This approach recognises obesity as a chronic metabolic condition requiring sustained pharmacological support, similar to how hypertension or diabetes are managed long-term. Your prescriber will review your treatment every 3-6 months to assess continued clinical benefit, tolerability, and appropriateness of ongoing therapy.

Stopping Wegovy: What Happens When You Discontinue Treatment?

Discontinuing Wegovy typically leads to weight regain in most patients, though the rate and extent vary individually. Research shows that without continued GLP-1 receptor agonist therapy, appetite-regulating hormones return to pre-treatment levels, and metabolic adaptations that supported weight loss begin to reverse [4].

If you need to stop Wegovy due to side effects, supply issues, or personal choice, your UK prescriber may recommend a gradual dose reduction rather than abrupt cessation. This tapering approach can help minimise rebound appetite increases and allows time to establish alternative weight management strategies, including dietary modifications, increased physical activity, or consideration of alternative licensed treatments.

Transitioning to Maintenance Strategies

Some patients successfully transition from Wegovy to lifestyle-based maintenance after 18-24 months of treatment, particularly those who have made substantial behavioural changes during therapy. Your prescriber will assess factors including weight loss achieved, metabolic improvements, and your confidence in maintaining results independently before supporting treatment discontinuation.

How Long to Take Wegovy for Weight Loss: Factors That Influence Duration

Individual treatment duration depends on multiple clinical factors beyond simple weight loss targets. Patients with obesity-related complications such as obstructive sleep apnoea, fatty liver disease, or cardiovascular risk factors may benefit from extended treatment even after achieving their initial weight goals [2].

Your starting BMI significantly influences recommended treatment duration. Patients beginning with BMI over 40 kg/m² typically require longer treatment periods (24+ months) to achieve clinically meaningful weight reduction compared to those starting with BMI 30-35 kg/m². Response rate also matters—if you achieve less than 5% weight loss after 12 weeks on the 2.4mg maintenance dose, your prescriber will reassess whether continuing Wegovy remains appropriate [5].

Personalised Treatment Plans at Cured Pharmacy

Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), creates individualised treatment plans based on your medical history, weight loss goals, and response to therapy. Regular clinical reviews ensure your Wegovy duration aligns with current NICE guidance and MHRA recommendations whilst optimising your long-term weight management outcomes.

Wegovy Treatment Duration UK: Getting Started at Cured Pharmacy

Starting Wegovy at Cured Pharmacy begins with a free online consultation completed in under 3 minutes. Our UK prescribers assess your suitability based on BMI, medical history, previous weight loss attempts, and current medications. If approved, your first prescription is dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery across the UK.

Wegovy is available from £79.00 at Cured Pharmacy, with transparent pricing shown before your consultation. All treatment includes ongoing prescriber support, with regular reviews to monitor your progress, manage any side effects, and adjust your treatment duration based on clinical response. Our lowest price guarantee ensures you receive genuine UK-licensed semaglutide at competitive rates without compromising on clinical care quality.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and clinical trial outcomes represent average responses across study populations.